{2-[ethyl(2-methoxybenzyl)amino]ethyl}carbamic acid benzyl ester | 616886-14-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: {2-[ethyl(2-methoxybenzyl)amino]ethyl}carbamic acid benzyl ester
• 英文别名: benzyl N-[2-[ethyl-[(2-methoxyphenyl)methyl]amino]ethyl]carbamate
• CAS: 616886-14-7
• 化学式: C₂₀H₂₆N₂O₃
• 分子量: 342.438
• InChiKey: OUBKOVVUJDYTKR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  25
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  50.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  {2-[ethyl(2-methoxybenzyl)amino]ethyl}carbamic acid benzyl ester 在 氢溴酸 、 溶剂黄146 作用下， 生成 N¹-ethyl-N¹-(2-methoxybenzyl)ethane-1,2-diamine
  参考文献：
  名称：

  新型的含醌多胺类化合物，可对抗阿尔茨海默氏病，是多靶点定向的配体。

  摘要：

  阿尔茨海默氏病（AD）的特征之一是其病因病理学的多因素性质，阻碍了发现有效的改变疾病的疗法。为了克服该缺点，最近提出了使用多靶标定向配体（MTDL）作为同时命中与AD综合征发展有关的多个靶标的手段。在本文中，一类基于聚胺-醌骨架的新型MTDL，其前导物（memoquin，2）在临床前研究中显示出令人鼓舞的特性（Cavalli等，Angew。Chem。，Int。Ed。2007，46，3689- 3692）。针对大量分离的与AD相关的靶标，即AChE和BChE，以及Abeta聚集（AChE介导和自我诱导），对3-29进行了体外测试。此外，

  DOI：

  10.1021/jm070559a
• 作为产物：
  描述：

  N-苄氧羰基乙二胺盐酸盐 在 sodium tetrahydroborate 、 3 A molecular sieve 作用下， 以 乙醇 、 甲苯 为溶剂， 反应 38.5h， 生成 {2-[ethyl(2-methoxybenzyl)amino]ethyl}carbamic acid benzyl ester
  参考文献：
  名称：

  Design, synthesis and biological evaluation of ambenonium derivatives as AChE inhibitors

  摘要：

  Ambenonium (1), an old AChE inhibitor, is endowed with an outstanding affinity and a peculiar mechanism of action that, taken together, make it a very promising pharmacological tool for the treatment of Alzheimer's disease (AD). Unfortunately, the bisquaternary structure of 1 prevents its passage through the blood brain barrier. In a search of centrally active ambenonium derivatives, we planned to synthesize tertiary amines of 1, such as 2 and 3. In addition, to add new insights into the binding mechanism of the inhibitor, we designed constrained analogues of ambenonium by incorporating the diamine functions into cyclic moieties (4-12). The biological evaluation of the new compounds has been assessed in vitro against human AChE and BChE. All tertiary amine derivatives resulted more than 1000-fold less potent than 1 and, unlike prototype, did not show any selectivity between the two enzymes. This result, because of recent findings concerning the role of BChE in AD, makes our compounds, endowed with a well-balanced profile of AChE/BChE inhibition, valuable candidates for further development. To better clarify the interactions that account for the high affinity of 1, docking simulations and molecular dynamics studies on the AChE-1 complex were also carried out.

  DOI：

  10.1016/s0014-827x(03)00150-2

文献信息

• [EN] 2,5-BIS-DIAMINE-'1,4! BENZOQUINONE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE A PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREFOR<br/>[FR] DERIVES DE BENZOQUINONE 2,5-BIS-DIAMINE-[1,4], UTILES POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER, LEURS PROCEDES DE PREPARATION ET INTERMEDIAIRES UTILISES DANS LEDIT PROCEDE
  申请人：ALMA MATER STUDIORUM

  公开号：WO2003087035A1

  公开（公告）日：2003-10-23

  2,5-bis-diamine-[1,4]benzoquinonic derivatives, having a general formula (I) have proved useful for the treatment of Alzheimer's disease; a method for preparing them and intermediates used in said method are also described. Fomula (I).

  2,5-双(二氨基)-[1,4]苯醌衍生物，具有通式（I），已被证明对治疗阿尔茨海默病有用；本文还描述了制备它们的方法和所使用的中间体。公式（I）：
• 2,5-Bis-diamine-'1,4! benzoquinone derivatives, for the treatment of alzheimer's disease a process for their preparation and intermediates therefor
  申请人：Andrisano Vincenza

  公开号：US20050261345A1

  公开（公告）日：2005-11-24

  2,5-bis-diamine-[1,4]benzoquinonic derivatives, having a general formula (I) have proved useful for the treatment of Alzheimer's disease; a method for preparing them and intermediates used in said method are also described.

  2,5-双(二氨基)-[1,4]苯醌衍生物，具有通式(I)，已被证明对治疗阿尔茨海默病有用；本文还描述了制备它们的方法和所使用的中间体。
• 2,5-BIS-DIAMINE-[1,4] BENZOQUINONE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE, A PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREFOR
  申请人：Alma Mater Studiorum -Universita' di Bologna

  公开号：EP1497257A1

  公开（公告）日：2005-01-19
• US7589219B2
  申请人：——

  公开号：US7589219B2

  公开（公告）日：2009-09-15
• Novel Class of Quinone-Bearing Polyamines as Multi-Target-Directed Ligands To Combat Alzheimer's Disease
  作者：Maria Laura Bolognesi、Rita Banzi、Manuela Bartolini、Andrea Cavalli、Andrea Tarozzi、Vincenza Andrisano、Anna Minarini、Michela Rosini、Vincenzo Tumiatti、Christian Bergamini、Romana Fato、Giorgio Lenaz、Patrizia Hrelia、Antonino Cattaneo、Maurizio Recanatini、Carlo Melchiorre

  DOI：10.1021/jm070559a

  日期：2007.10.1

  One of the characteristics of Alzheimer's disease (AD) that hinders the discovery of effective disease-modifying therapies is the multifactorial nature of its etiopathology. To circumvent this drawback, the use of multi-target-directed ligands (MTDLs) has recently been proposed as a means of simultaneously hitting several targets involved in the development of the AD syndrome. In this paper, a new

  阿尔茨海默氏病（AD）的特征之一是其病因病理学的多因素性质，阻碍了发现有效的改变疾病的疗法。为了克服该缺点，最近提出了使用多靶标定向配体（MTDL）作为同时命中与AD综合征发展有关的多个靶标的手段。在本文中，一类基于聚胺-醌骨架的新型MTDL，其前导物（memoquin，2）在临床前研究中显示出令人鼓舞的特性（Cavalli等，Angew。Chem。，Int。Ed。2007，46，3689- 3692）。针对大量分离的与AD相关的靶标，即AChE和BChE，以及Abeta聚集（AChE介导和自我诱导），对3-29进行了体外测试。此外，